NERV Key Statistics, Chart & Performance
The current stock price of NERV is 4.19 USD. In the past month the price increased by 10.85%. In the past year, price increased by 85.4%.
NERV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About NERV
Company Profile
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Company Info
MINERVA NEUROSCIENCES INC
1601 Trapelo Road, Suite 284
Waltham MASSACHUSETTS 02451 US
CEO: Remy Luthringer
Employees: 8
Phone: 16176007373
MINERVA NEUROSCIENCES INC / NERV FAQ
Can you describe the business of MINERVA NEUROSCIENCES INC?
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Can you provide the latest stock price for MINERVA NEUROSCIENCES INC?
The current stock price of NERV is 4.19 USD. The price increased by 5.54% in the last trading session.
What is the dividend status of MINERVA NEUROSCIENCES INC?
NERV does not pay a dividend.
How is the ChartMill rating for MINERVA NEUROSCIENCES INC?
NERV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MINERVA NEUROSCIENCES INC (NERV) stock?
6 analysts have analysed NERV and the average price target is 4.59 USD. This implies a price increase of 9.55% is expected in the next year compared to the current price of 4.19.
What is the Price/Earnings (PE) ratio of MINERVA NEUROSCIENCES INC (NERV)?
MINERVA NEUROSCIENCES INC (NERV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.32).
Can you provide the ownership details for NERV stock?
You can find the ownership structure of MINERVA NEUROSCIENCES INC (NERV) on the Ownership tab.
NERV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NERV. When comparing the yearly performance of all stocks, NERV is one of the better performing stocks in the market, outperforming 96.75% of all stocks.
NERV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NERV. NERV has a bad profitability rating. Also its financial health evaluation is rather negative.
NERV Financial Highlights
Over the last trailing twelve months NERV reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS increased by 31.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.93% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NERV Forecast & Estimates
6 analysts have analysed NERV and the average price target is 4.59 USD. This implies a price increase of 9.55% is expected in the next year compared to the current price of 4.19.